Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a fixed-dose combination product containing lansoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* (*H. pylori*). Lansoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. Amoxicillin and clarithromycin are antibiotics used to kill the bacteria.
## Primary Indications
* Eradication of *Helicobacter pylori* (*H. pylori*) infection in patients with peptic ulcer disease or gastric adenocarcinoma.
## Adult Dosing
The typical adult dose is one Soman HP capsule twice daily for 10 to 14 days. Each capsule contains lansoprazole 30 mg, amoxicillin 500 mg, and clarithromycin 250 mg.
* **Duration:** 10 to 14 days.
## Pediatric Dosing
Pediatric dosing for Sompraz HP is not established. Dosing of individual components (lansoprazole, amoxicillin, clarithromycin) may be available for pediatric use, but specific combination therapy regimens are not standardized.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment for lansoprazole is typically needed in mild to moderate renal impairment. Significant renal impairment may require dose adjustment of amoxicillin and clarithromycin. Consult specific prescribing information for amoxicillin and clarithromycin regarding renal dosing.
* **Hepatic Impairment:** No dose adjustment for lansoprazole is typically needed in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment. Consider dose adjustment for clarithromycin in hepatic impairment.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, other macrolides, or penicillins.
* History of severe immediate hypersensitivity reactions to beta-lactams.
* Concurrent use with cisapride, pimozide, thioridazine, or astemizole due to risk of QT prolongation.
* Severe hepatic impairment (clarithromycin component).
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, abdominal pain, headache, taste perversion, rash, and candidiasis. Serious adverse effects can include Clostridioides difficile-associated diarrhea, severe allergic reactions, liver dysfunction, and QT prolongation.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Clarithromycin is a moderate inhibitor of CYP3A4. Lansoprazole can also affect CYP enzymes. This combination may increase serum concentrations of drugs metabolized by CYP3A4 (e.g., warfarin, certain statins, anticonvulsants, immunosuppressants).
* **Warfarin:** Increased INR and bleeding risk.
* **Digoxin:** Increased digoxin levels.
* **Methotrexate:** May increase methotrexate levels.
* **Penicillin-binding agents:** May decrease the efficacy of amoxicillin.
* **Probenecid:** May decrease the renal excretion of amoxicillin.
## Monitoring
* Monitor for signs and symptoms of allergic reactions.
* Assess for effectiveness of *H. pylori* eradication (e.g., urea breath test, stool antigen test, or serologic testing) typically 4-8 weeks after completion of therapy.
* Monitor for signs of *Clostridioides difficile*-associated diarrhea.
* Evaluate liver function tests if symptoms arise.
## Clinical Pearls
* Administer the dose before a meal.
* Ensure patients complete the full course of therapy to maximize eradication rates and minimize the development of antibiotic resistance.
* Educate patients on potential side effects, especially gastrointestinal upset and diarrhea.
* If a patient is allergic to penicillin, an alternative *H. pylori* eradication regimen should be considered.
***
*This information is intended for clinical use and does not replace a thorough review of the most current prescribing information and relevant medical literature. Always verify current product labeling and guidelines before prescribing.*
